PulseSight Therapeutics is a biotechnology company based in France that specializes in ophthalmology drug development. The company is dedicated to developing disruptive non-viral gene therapies with minimally-invasive delivery technology to address major eye diseases and ultimately provide life-changing solutions for patients at risk of sight loss. Their most recent investment was a Seed Round raised on 28 February 2024, with participation from notable investors such as BB Pureos Bioventures, Korean Investment Partners, and ND Capital. PulseSight's innovative approach to ophthalmic treatments, coupled with their strong investor backing, positions them as a promising player in the biotechnology sector, with significant potential for growth and impact within the healthcare industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 3 |
|
28 Feb 2024 |
No recent news or press coverage available for PulseSight Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
